Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | DRD1 | P21728 | 1/20 | 0.33 |
| ▸ | DRD5 | P21918 | 2/20 | 0.31 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20355507 | 0.74 | JAK3 (0.33) | IRAK4 | |
| SCHEMBL4630787 | 0.70 | HPGD (0.35) | — | |
| SCHEMBL29157521 | 0.69 | DDB1 (0.55) | DRD1 | |
| SCHEMBL5479824 | 0.68 | DDB1 (0.40) | — | |
| SCHEMBL28111070 | 0.68 | DDB1 (0.31) | — | |
| SCHEMBL2217683 | 0.65 | SLC6A4 (0.39) | — | |
| SCHEMBL1240861 | 0.64 | EPHX2 (0.39) | — | |
| SCHEMBL739596 | 0.64 | PSEN1 (0.41) | — | |
| SCHEMBL1242072 | 0.63 | DDB1 (0.52) | — | |
| SCHEMBL1717738 | 0.63 | DDB1 (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1470103-B1 | AMIDOACETONITRILE DERIVATIVES | NOVARTIS AG (CH) | 2008-05-14 | — | — | EP | disclosed |
| US-7153814-B2 | Amidoacetonitrile derivatives | NOVARTIS ANIMAL HEALTH US, INC. (US) | 2006-12-26 | — | — | US | disclosed |
| US-20050059736-A1 | Amidoacetonitrile derivatives | NOVARTIS ANIMAL HEALTH US, INC. | 2005-03-17 | — | — | US | disclosed |
| EP-1470103-A1 | AMIDOACETONITRILE DERIVATIVES | Novartis AG (CH) | 2004-10-27 | — | — | EP | disclosed |
| WO-2003059868-A1 | AMIDOACETONITRILE DERIVATIVES | NOVARTIS AG (CH) | 2003-07-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050059736-A1 | Amidoacetonitrile derivatives | ARG1, NAT1, NMBR | DRD2 1486/4885DRD1 857/4885DRD5 2511/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.